In search of the perfect steroid

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 2 SUPPL. 2, 2007, Pages

  Bielory, Leonard ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CORTICOTROPIN; CORTISONE ACETATE; FLUNISOLIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; SALBUTAMOL; STEROID; TRIAMCINOLONE ACETONIDE;

AMENORRHEA; ANXIETY DISORDER; ARTICLE; ASEPTIC NECROSIS; ASTHMA; BONE DENSITY; BRAIN ATROPHY; BRAIN EDEMA; CATARACT; CHOLESTEROL BLOOD LEVEL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPHONIA; EPILEPSY; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GROWTH DISORDER; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPEROSMOLAR COMA; HYPERTENSION; HYPOKALEMIC ALKALOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; MENTAL DISEASE; MOUTH DISEASE; MYOPATHY; OBESITY; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PHARYNGITIS; PHARYNX DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SKIN DEFECT; SODIUM RETENTION; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE; WATER RETENTION; WOUND HEALING IMPAIRMENT;

EID: 33846813747     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60702-8     Document Type: Article

References (54)

1. Solis-Cohen S. The use of adrenal substance in the treatment of asthma. JAMA. 1900;34:1164-1166.
2. Lichtenstein LM. An evaluation of the role of immunotherapy in asthma. Am Rev Respir Dis. 1978;117:191.
3. Clark TJH. Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy. Auckland, New Zealand: ADIS Press; 1983.
4. Herzog HL, Nobile A, Tolksdorf S, et al. New antiarthritic steroids. Science. 1955;121:176.
5. Herzog HL. 11-Oxygenated steroids. J Am Chem Soc. 1955;77: 4781-4784.
6. Nobile A. Microbiological transformation of steroids. Am J Chem Soc. 1955;77:4184.
7. Bunim JJ, Pechet MM, Bollet AJ. Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. JAMA. 1955;157:311-318.
8. US Food and Drug Administration. Department of Health and Human Services. Drugs@FDA. Available at www. accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed March 2006.
9. Herzog H, Oliveto EP. A history of significant steroid discoveries and developments originating at the Schering Corporation (USA) since 1948. Steroids. 1992;57:617-623.
10. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
11. Lukert B. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, CA: Academic Press; 1996.
12. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 suppl):S1-S40.
13. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004;44:37-47.
14. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469-478; quiz 479.
15. Ververeli K, Chipps B. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann Allergy Asthma Immunol. 2004;92:512-522.
16. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary- adrenal axis suppression in asthmatics inhal-ing high dose corticosteroids. Respir Med. 1991;85:501-510.
17. Brown PH, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatic adults taking high dose beclomethasone dipropionate. Br J Clin Pract. 1992;46:102-104.
18. Davies G, Thomas P, Broder I, et al. Steroid-dependent asthma treated with inhaled beclomethasone dipropionate: a long-term study. Ann Intern Med. 1977;86:549-553.
19. Kass I, Vijayachandra Nair S, Patil KD. Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthmatic patients: an assessment of 18 months of therapy. Chest. 1977;71:703-707.
20. Lee-Hong E, Collins-Williams C. The long-term use of beclomethasone dipropionate for the control of severe asthma in children. Ann Allergy. 1977;38:242-244.
21. Smith MJ, Hodson ME. High-dose beclomethasone inhaler in the treatment of asthma. Lancet. 1983;1:265-269.
22. Williams MH Jr. Treatment of asthma with triamcinolone acetonide aerosol. Chest. 1975;68:765-768.
23. Sly RM, Imseis M, Frazer M, Joseph F. Treatment of asthma in children with triamcinolone acetonide aerosol. J Allergy Clin Immunol. 1978;62:76-82.
24. Slavin RG, Izu AE, Bernstein IL, et al. Multicenter study of flunisolide aerosol in adult patients with steroid-dependent asthma. J Allergy Clin Immunol. 1980;66:379-385.
25. Shapiro GG, Izu AE, Furukawa CT, Pierson WE, Bierman CW. Short-term double-blind evaluation of flunisolide aerosol for steroid-dependent asthmatic children and adolescents. Chest. 1981;80:671-675.
26. Orgel HA, Meltzer EO, Kemp JP. Flunisolide aerosol in treatment of steroid-dependent asthma in children. Ann Allergy. 1983;51(1 pt 1):21-25.
27. Harrison LI. Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. J Aerosol Med. 2002;15:401-406.
28. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196-208.
29. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
30. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353.
31. Feddah MR, Brown KF, Gipps EM, Davies NM. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci. 2000;3:318-324.
32. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
33. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(suppl 39):1-34.
34. Barnes P, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med. 1998;157(3 suppl, pt 2):S1-S53.
35. O'Connell EJ. Review of the unique properties of budesonide. Clin Ther. 2003;25(suppl C):C42-C60.
36. Joshi M, Misra AN. Pulmonary disposition of budesonide from liposomal dry powder inhaler. Methods Find Exp Clin Pharmacol. 2001;23:531-536.
37. Aksoy MO, Li X, Borenstein M, Yi Y, Kelsen SG. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol. 1999;103:1081-1091.
38. Pearlman DS, Noonan MJ, Tashkin DP, et al. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol. 1997;78:356-362.
39. Wasserman SI, Gross GN, Schoenwetter WF, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma. 1996;33:265-274.
40. Wolfe JD, Seiner JC, Mendelson LM, Hampel F Jr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther. 1996;18:635-646.
41. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med. 1998;92:95-104.
42. Donnelly R, Williams KM, Baker AB, et al. Effects of budesonide and fluticasone on 24-hour plasma cortisol: a dose-response study. Am J Respir Crit Care Med. 1997;156:1746-1751.
43. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996;51:262-266.
44. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383.
45. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
46. Grahnen A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol. 1997;52:261-267.
47. Wilson AM, McFarlane LC, Lipworth BJ. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med. 1997;156(4 pt 1):1274-1277.
48. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 1994;38:521-525.
49. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 1996;9:1427-1432.
50. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213-219.
51. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet. 1996;348:27-29.
52. Law CM, Marchant JL, Honour JW, Preece MA, Warner JO. Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet. 1986;1:942-944.
53. Halterman JS. Providers underestimate symptom severity among urban children with asthma. Arch Pediatr Adolesc Med. 2002;156:141-146.
54. Rosenwasser LJ, Nash DB. Incorporating omalizumab into asthma treatment guidelines: consensus panel recommendations. P&T. 2003;28:400-410.